The shares were acquired at an average cost of $7.53 per share, for a total transaction of $82,830.00.
On Tuesday, May 2nd, Phillip Md Et Al Frost bought 15,000 shares of Opko Health stock. The shares were acquired at an average price of $8.45 per share, with a total value of $30,420.00.
On Friday, May 5th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average price of $7.81 per share, with a total value of $175,725.00.
The SMA or Simple Moving Averages are commonly available for 20 Day, 50 Day and 200 Day Simple Moving Averages.
On Wednesday, April 26th, Phillip Md Et Al Frost purchased 5,000 shares of Opko Health stock. On average, analysts anticipate that Opko Health Inc. will post ($0.14) earnings per share for the current fiscal year. The shares were acquired at an average price of $7.48 per share, with a total value of $142,120.00.
01/03/2017 - Opko Health Inc had its "buy" rating reiterated by analysts at Ladenburg Thalmann. (NASDAQ:OPK) traded down 6.839% during midday trading on Wednesday, hitting $7.015. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. The firm's stock has a market capitalization of $4.2 bln.
Stock is now moving with a negative distance from the 200 day simple moving average of approximately -24.76%, and has a poor year to date (YTD) performance of -24.73% which means the stock is constantly subtracting to its value from the previous fiscal year end price.
Ims Capital Management decreased Opko Health Inc (OPK) stake by 63.88% reported in 2016Q4 SEC filing.
5 analysts on average are expecting Opko Health, Inc.to report earnings of $-0.03 per share for the current quarter. The business had revenue of $296.10 million during the quarter, compared to analyst estimates of $313.36 million.
Noble Group shares down 23% in wake of profit warning
The company's net debt to capital stood at 46 percent as of March 31, in line with the group's stated target of 45 to 50 percent. But its shares have crashed by around 90 per cent from mid-February 2015 when Iceberg first issued its report.
The stock has Return on Assets (ROA) of -0.9 percent. The firm's revenue was down.3% compared to the same quarter a year ago.
ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem.
The analysts offering 12 month price targets for Opko Health, Inc. have a median target of $15.5, with a high estimate of $25 and a low estimate of $8.
Several analysts recently commented on the stock. Comerica Bank bought a new stake in Opko Health during the fourth quarter worth about $117,000. AQR Capital Management LLC purchased a new stake in Opko Health during the fourth quarter valued at $105,000. Formidable Asset Management LLC increased its position in Opko Health by 10.4% in the fourth quarter. Wells Fargo & Company MN now owns 699,650 shares of the biotechnology company's stock worth $5,597,000 after buying an additional 290,084 shares during the last quarter.
Shares outstanding are recorded as 557.11 M and total shares floated are 338.89 M. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 1.80. The company's market cap is $3.90 billion. The most recent short interest data show 22.13% of the company's stock are short sold.
A number of analysts recently issued reports on the company.
A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. In this case, shares are down -40.33% from $12.15, the 52-week high touched on December 15, 2016, but are collecting gains at -25.49% for the past 12 months. Guggenheim began coverage on Opko Health in a research report on Tuesday, March 14th. The stock has dropped -3.87% from its peak and the consensus price target for the stock is $40.18 a share. Chicago-based equity research firm Zacks Investment Research has assigned this stock ABR (Average Brokerage Recommendation) of 1.4, indicating analysts in general look favorably on the company's future prospects. Opko Health now has a consensus rating of "Hold" and a consensus target price of $15.64.
OPKO Health, Inc.is a healthcare company.
Comments